Propafenone Use in Structural Heart Disease and Heart Failure
Contraindications and Alternative Options
- The European Heart Journal recommends that propafenone should be completely avoided in patients with heart failure or reduced left ventricular ejection fraction 1, 2, 3
- The European Heart Journal suggests that amiodarone is the preferred antiarrhythmic agent in patients with structural heart disease, including those with heart failure 4, 5
- Sotalol may be used in patients with ischemic heart disease but without severe heart failure, as recommended by the European Heart Journal 5
Monitoring and Risk Assessment
- Regular ECG monitoring is essential during initiation and dose adjustments of propafenone in patients with mild structural abnormalities, as recommended by the European Heart Journal 5
- Monitor for QRS prolongation; an increase in QRS duration >25% from baseline indicates potential proarrhythmic risk, according to the European Heart Journal 5
Mechanisms of Risk
- Propafenone can precipitate ventricular tachycardia, ventricular fibrillation, and intraventricular conduction disturbances, as reported in Circulation 2